

Nanoencapsulation of Mycolic acids as a deliverable to macrophages

^{a,b}Benadie, Y., ^bSemete, B., ^aVenter, L., ^bKalombo L., ^aDriver, C., ^cJones, A.T., ^bSwai, H. and ^aVerschoor, J.A.

^aDepartment of Biochemistry, University of Pretoria, Pretoria, South Africa

^bPolymers and Bioceramics, MSM, CSIR, Pretoria, South Africa

^cWelsh School of Pharmacy, Cardiff University, United Kingdom

Introduction

Asthma is a reaction to environmental antigens causing a chronic inflammatory disease by a Th2 response. Mycolic acids (MA), depicted in Fig.1, which are part of the cell envelope of *Mycobacterium tuberculosis*, were shown to have potential as immunotherapeutic agents in a mouse model of asthma¹. Due to the extremely hydrophobic nature of mycolic acids, a suitable vehicle is needed to introduce them into the body and guide them to their natural macrophage targets. Previously liposomes were used, but a more stable vehicle was desired.

The **objective** of this project was to explore the encapsulation of mycolic acids into vehicles other than liposomes for delivery into macrophages and addressing the challenge of low solubility. As vehicles nanoparticles (NP) have the advantage over liposomes in that they can increase the stability of the drug as well as effect controlled release of the agent as a function of *in vivo* particle degradation².




Fig.1 Generalised structures of MA from *Mycobacterium tuberculosis*. Hydrocarbon chain lengths are indicated as a, b or c, to a total of around 90 carbons per mycolic acid.

Experimental and Results

In liposomes composed of egg phosphatidylcholine and cholesterol and that were loaded with mycolic acids, transfer of the labeled MA to unloaded liposomes occurred very rapidly (within 5 minutes) at 37 °C as determined by flow cytometry. The process could not be slowed down at 2 °C to an extent that would allow elucidation of the mechanism of MA redistribution within the first five minutes after mixing the loaded and unloaded liposomes. This called for an alternative delivery vehicle other than liposomes to ensure focused delivery of the MA to the macrophages, without dilution of the MA content in the general circulation.




Fig.2 The mean % fluorescence distribution of liposomes at 37 °C and 2 °C. Original labeled MA (black), unlabeled MA (grey), the mixed population (white). The value of the mixed population is a mean value for 7 (SD 8.39; 37 °C) and 3 (SD 6.17; 2 °C) measurements respectively. All liposomes contained the same amount of PC (90 µl) and cholesterol (45 µl).

To prepare nanoparticles, Poly lactide-glycolide (PLGA) was used to prepare a multiple nano emulsion with fluorescently labeled MA³ and the emulsion was subsequently freeze dried. The resulting nanoparticles were characterised based on size, zeta potential and morphology. The SEM image (Fig.3) indicated the formation of nanoparticles. Because only the MA and not PLGA co-polymer is fluorescently labeled with 5-Bromomethylfluorescein⁴ in the nanoparticle, fluorescent images (Fig.4) confirmed that the MA was indeed part of the nanoparticle matrix.




Fig.3 SEM of MA PLGA nanoparticles with an average size of 490-509 nm measured by a zeta sizer.




Fig.4 Fluorescence measurement excited by a 488 nm laser indicating labeled MA as part of the PLGA nanoparticles.

THP-1 and U937 monocyte-macrophage like cell lines which are often used in nanoparticle uptake studies^{5,6}, were used to determine whether the labeled MA nanoparticles would be taken up by the cells. The MA containing nanoparticles were incubated with the respective macrophage cell lines. The particle uptake was analyzed over a period of time via confocal microscopy. The data as presented in Fig 5 illustrated that labeled MA nanoparticles were successfully taken up into the macrophage cells. This demonstrates that nanoparticles may serve as a suitable carrier for MA to reach their target sites.




Fig.5 Live cell image of labeled MA nanoparticles taken up by a) THP-1 and b) U937 macrophages.

Discussion and conclusion

This study is the first to report successful encapsulation of MA into solid matrix like PLGA nanoparticles. The study aimed to assess the potential of PLGA nanoparticles as alternative carriers of pharmaceutical agents to be taken up in the body and processed in macrophages to deliver their beneficial biological effects to patients. In particular, MA was investigated, a highly hydrophobic molecule, as pharmaceutical agent that may be beneficial for the cure of asthma. Current research is focused on uptake and localization studies within macrophages.

Acknowledgements

The authors thank the Council for Scientific and Industrial Research (CSIR), University of Pretoria and the National Research Foundation (NRF) for funding this study.

References

- 1) Korf J.E., et al., Macrophage Reprogramming by Mycolic Acid promotes a tolerogenic response in experimental asthma. *Am J Respir Crit Care Med* 2006. 174. p 152-160.
- 2) Soppimath, K.S., et al., Biodegradable polymeric nanoparticles as drug delivery devices. *J Control Release*, 2001. 70(1-2): p. 1-20.
- 3) Jain, R.A., The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. *Biomaterials*, 2000. 21(23): p. 2475-90.
- 4) Butler, W.R. and L.S. Guthertz, Mycolic acid analysis by high-performance liquid chromatography for identification of *Mycobacterium* species. *Clin Microbiol Rev*, 2001. 14(4): p. 704-26.
- 5) Spano, K.O., et al., Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular *Mycobacterium tuberculosis*. *Int J Pharm*, 2007. 345 p 154-162.
- 6) Yi Sun, E., Development of Nanoparticle Libraries for Biosensing. *Bioconjugate Chem*. 2006, 17, 109-113